Pharmacotherapy in sickle cell disease—state of the art and future prospects. (يفتح نافذة جديدة)

Hankins J, Aygun B.

Source‎: Br J Haematol 2009;145(3):296-308.

مفهرسة‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (يفتح نافذة جديدة)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (يفتح نافذة جديدة)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Source‎: Blood 2005;106(7):2269-75.

مفهرسة‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (يفتح نافذة جديدة)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (يفتح نافذة جديدة)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Source‎: N Engl J Med 2020;382(26):2524-33.

مفهرسة‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (يفتح نافذة جديدة)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (يفتح نافذة جديدة)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Source‎: Br J Haematol 2013;161(6):852-60.

مفهرسة‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (يفتح نافذة جديدة)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (يفتح نافذة جديدة)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Source‎: Arch Dis Child 2013;98(11):908-14.

مفهرسة‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (يفتح نافذة جديدة)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (يفتح نافذة جديدة)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Source‎: Pediatrics 2008;122(6):1332-42.

مفهرسة‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (يفتح نافذة جديدة)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (يفتح نافذة جديدة)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Source‎: Blood 2012;120(22):4304-10.

مفهرسة‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (يفتح نافذة جديدة)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (يفتح نافذة جديدة)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Source‎: N Engl J Med 2019;380(2):121-31.

مفهرسة‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (يفتح نافذة جديدة)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (يفتح نافذة جديدة)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Source‎: J Pediatr 2002;140(2):225-9.

مفهرسة‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (يفتح نافذة جديدة)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (يفتح نافذة جديدة)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Source‎: Pediatrics 2013;132(4):677-83.

مفهرسة‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (يفتح نافذة جديدة)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (يفتح نافذة جديدة)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Source‎: Lancet 2011;377(9778):1663-72.

مفهرسة‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (يفتح نافذة جديدة)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (يفتح نافذة جديدة)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Source‎: Lancet 2016;387(10019):661-70.

مفهرسة‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (يفتح نافذة جديدة)

How I use hydroxyurea to treat young patients with sickle cell anemia. (يفتح نافذة جديدة)

Ware RE.

Source‎: Blood 2010;115(26):5300-11.

مفهرسة‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (يفتح نافذة جديدة)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (يفتح نافذة جديدة)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Source‎: Blood 2004;103(6):2039-45.

مفهرسة‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (يفتح نافذة جديدة)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (يفتح نافذة جديدة)

Hirst C, Owusu-Ofori S.

Source‎: Cochrane Database Syst Rev 2012;(9):CD003427.

مفهرسة‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (يفتح نافذة جديدة)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (يفتح نافذة جديدة)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Source‎: Lancet Haematol 2021;8(5):e323-33.

مفهرسة‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (يفتح نافذة جديدة)

Sickle cell disease. (يفتح نافذة جديدة)

Meremikwu MM, Okomo U.

Source‎: BMJ Clin Evid 2011;02:2402.

مفهرسة‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (يفتح نافذة جديدة)

A phase 3 trial of l-glutamine in sickle cell disease. (يفتح نافذة جديدة)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Source‎: N Engl J Med 2018;379(3):226-35.

مفهرسة‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (يفتح نافذة جديدة)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (يفتح نافذة جديدة)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Source‎: Blood. 2023 23;141(12):1402-10.

مفهرسة‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (يفتح نافذة جديدة)

Malaria chemoprophylaxis in sickle cell disease. (يفتح نافذة جديدة)

Oniyangi O, Omari AA.

Source‎: Cochrane Database Syst Rev 2006;(4):CD003489.

مفهرسة‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (يفتح نافذة جديدة)